Skip to search formSkip to main contentSkip to account menu

TOR complex 2

Known as: mTOR Complex 2, Target of Rapamycin Complex 2, TORC2 
A protein complex that is involved in both serine/threonine phosphorylation and cytoskeleton remodeling in response to cellular stress.
National Institutes of Health

Related topics

Related topics

7 relations
DEP Domain-Containing mTOR-Interacting ProteinFRAP1 protein, humanMTOR geneSerine/Threonine Phosphorylation

Broader (2)

FKBP12-rapamycin associated proteinMultiprotein Complexes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The Kinase Complex mTOR Complex 2 Promotes the Follicular Migration and Functional Maturation of Differentiated Follicular Helper CD4+ T Cells During Viral Infection
Follicular helper CD4+ T (TFH) cells are critical for optimal B-cell-mediated humoral immunity by initiating, fueling, and… 
2011
2011
Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.
The mammalian target of rapamycin (mTOR) is centrally involved in growth, survival and metabolism. In cancer, mTOR is frequently… 
2010
2010
A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.
3015 Background: The PI3K pathway is frequently dysregulated in cancer cells and has been implicated as a mechanism of resistance… 
2010
2010
Phorbol Ester-Induced Human Cytomegalovirus Major Immediate-Early (MIE) Enhancer Activation through PKC-Delta, CREB, and NF-κB Desilences MIE Gene Expression in Quiescently Infected Human Pluripotent…
ABSTRACT The ways in which human cytomegalovirus (HCMV) major immediate-early (MIE) gene expression breaks silence from latency… 
Highly Cited
2010
Highly Cited
2010
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced…
3030 Background: XL765 is a potent and selective inhibitor of class I PI3K isoforms, TORC1, and TORC2. XL765 has shown dose… 
2010
2010
Glycogen Synthase Kinase-3 Is Required for Efficient Dictyostelium Chemotaxis
We present a new role for glycogen synthase kinase (GSK) in the regulation of aggregation and chemotaxis in Dictyostelium. GSK… 
2009
2009
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors.
3502 Background: XL765 is a potent and selective inhibitor of Class I PI3K isoforms, TORC1, and TORC2. XL765 has shown dose… 
2009
2009
Breaking Human Cytomegalovirus Major Immediate-Early Gene Silence by Vasoactive Intestinal Peptide Stimulation of the Protein Kinase A-CREB-TORC2 Signaling Cascade in Human Pluripotent Embryonal…
ABSTRACT The triggering mechanisms underlying reactivation of human cytomegalovirus (HCMV) in latently infected persons are… 
2008
2008
MHC class I and integrin ligation induce ERK activation via an mTORC2-dependent pathway.
Highly Cited
2007
Highly Cited
2007
Probing the membrane environment of the TOR kinases reveals functional interactions between TORC1, actin, and membrane trafficking in Saccharomyces cerevisiae.
The TOR kinases are regulators of growth in eukaryotic cells that assemble into two distinct protein complexes, TORC1 and TORC2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)